Test, evidence, transition projects in Scotland: developing the evidence needed for transition of effective interventions in cancer care from innovation into mainstream practice.
Breast cancer
Cancer diagnosis
Evaluation
Implementation science
Prostate cancer
Scotland
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
23
10
2023
accepted:
30
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
A robust evidence base is required to assist healthcare commissioners and providers in selecting effective and sustainable approaches to improve cancer diagnosis and treatment. Such evidence can be difficult to build, given the fast-paced and highly pressured nature of healthcare delivery, the absence of incentives, and the presence of barriers in conducting pragmatic yet robust research evaluations. Cancer Research UK (CRUK) has played an active part in building the evidence base through its funding of programmes to identify, evaluate and scale-up innovative approaches across the UK. The aim of this paper is to describe and explain the research design and intended approach and activities for two cancer services improvement projects in Scotland funded by CRUK. A hybrid effectiveness-implementation study design will assess both the efficiency of the new pathways and their implementation strategies, with the aim of generating knowledge for scale-up. A range of implementation, service and clinical outcomes will be assessed as determined by the projects' Theories of Change (ToCs). A naturalistic case study approach will enable in-depth exploration of context and process, and the collection and synthesis of data from multiple sources including routine datasets, patient and staff surveys, in-depth interviews and observational and other data. The evaluations are informed throughout by a patient/public representatives' group, and by small group discussions with volunteer cancer patients. Our approach has been designed to provide a holistic understanding of how (well) the improvement projects work (in relation to their anticipated outcomes), and how they interact with their wider contexts. The evaluations will help identify barriers, facilitators, and unanticipated consequences that can impact scalability, sustainability and spread. By opting for a pragmatic, participatory evaluation research design, we hope to inform strategies for scaling up successful innovations while addressing challenges in a targeted manner.
Sections du résumé
BACKGROUND
BACKGROUND
A robust evidence base is required to assist healthcare commissioners and providers in selecting effective and sustainable approaches to improve cancer diagnosis and treatment. Such evidence can be difficult to build, given the fast-paced and highly pressured nature of healthcare delivery, the absence of incentives, and the presence of barriers in conducting pragmatic yet robust research evaluations. Cancer Research UK (CRUK) has played an active part in building the evidence base through its funding of programmes to identify, evaluate and scale-up innovative approaches across the UK. The aim of this paper is to describe and explain the research design and intended approach and activities for two cancer services improvement projects in Scotland funded by CRUK.
METHODS
METHODS
A hybrid effectiveness-implementation study design will assess both the efficiency of the new pathways and their implementation strategies, with the aim of generating knowledge for scale-up. A range of implementation, service and clinical outcomes will be assessed as determined by the projects' Theories of Change (ToCs). A naturalistic case study approach will enable in-depth exploration of context and process, and the collection and synthesis of data from multiple sources including routine datasets, patient and staff surveys, in-depth interviews and observational and other data. The evaluations are informed throughout by a patient/public representatives' group, and by small group discussions with volunteer cancer patients.
DISCUSSION
CONCLUSIONS
Our approach has been designed to provide a holistic understanding of how (well) the improvement projects work (in relation to their anticipated outcomes), and how they interact with their wider contexts. The evaluations will help identify barriers, facilitators, and unanticipated consequences that can impact scalability, sustainability and spread. By opting for a pragmatic, participatory evaluation research design, we hope to inform strategies for scaling up successful innovations while addressing challenges in a targeted manner.
Identifiants
pubmed: 37915009
doi: 10.1186/s12885-023-11592-w
pii: 10.1186/s12885-023-11592-w
pmc: PMC10619322
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049Subventions
Organisme : Cancer Research UK
ID : PICATR-2022/100023 and PICATR-2022/100014
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Syst Rev. 2020 Apr 26;9(1):94
pubmed: 32336290
Res Involv Engagem. 2022 Nov 4;8(1):58
pubmed: 36333757
Lancet Oncol. 2015 Sep;16(12):1231-72
pubmed: 26431866
Health Res Policy Syst. 2019 Sep 13;17(1):84
pubmed: 31519185
Health Soc Care Community. 2019 Jul;27(4):1085-1094
pubmed: 30723977
Psychiatry Res. 2020 Jan;283:112376
pubmed: 31036287
Int J Behav Nutr Phys Act. 2022 Mar 28;19(1):33
pubmed: 35346233
BMJ. 2017 Aug 2;358:j3453
pubmed: 28768629
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
Eur J Ageing. 2004 Dec;1(1):73-78
pubmed: 28794704
Health Res Policy Syst. 2020 Jan 3;18(1):1
pubmed: 31900230
Clin Oncol (R Coll Radiol). 2022 Jul;34(7):430-435
pubmed: 35256220
BMJ Open. 2020 Apr 8;10(4):e033516
pubmed: 32273313
Br J Gen Pract. 2016 Apr;66(645):176-7
pubmed: 27033479
Int J Cancer. 2021 Feb 1;148(3):601-608
pubmed: 32706917
Health Technol Assess. 2021 Sep;25(57):1-132
pubmed: 34590577
Implement Sci. 2015 Mar 10;10:31
pubmed: 25889831